Desloratadine in the treatment of nasal congestion in seasonal allergic rhinitis: Preclinical and clinical evidence

Clinical Drug Investigation

Volumn 22, Issue SUPPL. 2, 2002, Pages 21-32

  Scadding, Glenis K ^a  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; CELL ADHESION MOLECULE; CHEMOKINE; CORTICOSTEROID; CYTOKINE; DESLORATADINE; EOTAXIN; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; KININ; LEUKOTRIENE C4; NEUROTRANSMITTER; PADGEM PROTEIN; PROSTAGLANDIN D2; RANTES; SEROTONIN 1 ANTAGONIST; SUBSTANCE P; TRYPTASE;

ALLERGIC RHINITIS; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; MEDIATOR RELEASE; NONHUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 0036323982     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222002-00003     Document Type: Review

References (86)

1. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis
2. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
3. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis
4. Effect of desloratadine versus placebo on nasal airflow and subjective measure of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen exposure unit
5. Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study
6. Nasal obstruction as a risk factor for sleep-disordered breathing
7. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids
8. Desloratadine: A new nonsedating, oral antihistamine
9. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)
10. 1-antagonist, descarboethoxy-loratadine
11. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
12. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine
13. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells
14. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines
15. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1-and H2 receptor antagonists
16. Loratadine reduces RANTES release by an epithelial cell line
17. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells
18. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells
19. Molecular and cellular mechanisms of allergic disease
20. Advances in immunology: Allergy and allergic diseases (part one of two)
21. Systemic activation of basophils and eosinophils: Markers and consequences
22. Eosinophil trafficking to sites of allergic inflammation
23. Mast cells, basophils, and eosinophils: Distinct but overlapping pathways for recruitment
24. Rhinomanometry
25. Die wiener provokations kammer (Vienna Challenge Chamber) -eine neue methode des allergen-expositionstests
26. Effects of H1-receptor antagonists on nasal obstruction in atopic patients
27. Assessment of nasal obstruction: A comparison between rhinomanometry and nasal inspiratory peak flow
28. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow
29. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis
30. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis
31. Adrenoreceptors in the control of human nasal mucosal blood flow
32. Nasal decongestant activity of pseudoephedrine
33. Mediator release during nasal provocation: A model to investigate the pathophysiology of rhinitis
34. Perceptual and physiologic effects of histamine challenge on nasal breathing
35. Intranasal histamine challenge in normal subjects and allergic rhinitis before and after intranasal budesonide studied with rhinostereometry and micromanipulator-guided laser Doppler flowmetry
36. Rhinostereometry and laser Doppler flowmetry in human nasal mucosa: Changes in congestion and microcirculation during intranasal histamine challenge
37. Changes in nasal resistance and nasal geometry using pressure and acoustic rhinometry in a feline model of nasal congestion
38. Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine
39. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season
40. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion
41. Pharmacology of nasal provocation with bradykinin: Studies of tachyphylaxis, cyclooxygenase inhibition, alpha-adrenergic stimulation, and receptor subtype
42. Nasal effects of bradykinin and capsaicin: Influence on plasma protein leakage and role of sensory neurons
43. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy
44. Role of kinins in seasonal allergic rhinitis: Icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen
45. Nasal reactivity to capsaicin in patients with seasonal allergic rhinitis during and after the pollen season
46. Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation
47. Current immunohistochemical results of localization of vasoactive intestinal polypeptide (VIP) in nasal mucosa of the human
48. Sensory neuropeptides and nitric oxide in nasal vastochemical regulation
49. Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen
50. Effects of intravenous infusions of prostaglandin D2 in man
51. Inflammatory mediators in late antigen-induced rhinitis
52. Nasal response to a single antigen challenge in patients with allergic rhinitis: Inflammatory cell recruitment persists up to 48 hours
53. Mediator release after allergic and physical nasal challenges
54. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis
55. Effects of nasal challenge with histamine, leukotriene C4 and prostaglandin D2 in patients with grass-pollen allergic rhinitis
56. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
57. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis
58. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor
59. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy
60. The effect of IL-4 on human nasal mucosal responses
61. Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation
62. A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis
63. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis
64. RANTES induces nasal mucosal inflammation rich in eosinophils, basophils, and lymphocytes in vivo
65. Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis
66. Secretion of chemokines and other cytokines in allergen-induced nasal responses: Inhibition by topical steroid treatment
67. Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa
68. Novel co-operation between eotaxin and substance-P in inducing eosinophil-derived neurotoxin release
69. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment
70. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: Its key role in eosinophil recruitment in nasal mucosa
71. Chemokines induce eosinophil degranulation through CCR-3
72. Cytologic changes in the nasal secretions during the late nasal response
73. Interleukin-5 and interleukin-8 in relation to eosinophils and neutrophils in nasal fluids from school children with seasonal allergic rhinitis
74. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways
75. Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps
76. P- and L-selectin mediate binding of T cells to chronically inflamed human airway endothelium
77. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge
78. Pharmacology of desloratadine: Special characteristics
79. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation
80. Effect of loratadine and SCH 34117 on superoxide anion production from human polymorphonuclear neutrophils and monocytes
81. The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: A placebo-controlled randomized study
82. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis
83. Desloratadine relieves nasal congestion in patients with seasonal allergic rhinitis
84. Desloratadine reduced nasal congestion in patients with seasonal rhinitis and asthma
85. Desloratadine improved asthma symptoms and decreased β2 agonist use in patients with seasonal allergic rhinitis and asthma
86. Fixed-dose desloratadine and pseudoephedrine relieves moderate/severe nasal congestion in patients with seasonal allergic rhinitis